
This just happened, and it changes the timeline conversation
ANVISA’s transition deadline under RDC 843/2024 expired three days ago. Supplements and weight-control foods that had been operating under the old local notification system were required to complete formal ANVISA notification by that date. If your brand, or a partner you’re evaluating in Brazil, is still relying on outdated guidance about “future deadlines,” that information is now obsolete.
What actually happened on September 1, 2026
Brazil’s supplement regularization model changed structurally with RDC 843/2024, in effect since September 1, 2024. It moved most supplements away from a simple local health surveillance notice (“comunicado”) to formal notification directly with ANVISA, the federal agency, based on a risk-tiered model. Products that had been operating under the old local system, and hadn’t yet completed the new ANVISA notification, had until September 1, 2026 to do so, per RDC 990/2025, which amended the original deadline.
What happens to products that missed the deadline
| Track | Consequence of missing the deadline |
|---|---|
| Products requiring registration adequacy | Cancellation of registration |
| Products requiring notification | Product can no longer be legally offered on the market |
| Both cases | Considered a sanitary infraction, subject to penalties |
What this deadline does NOT cover
ANVISA was specific about scope: the expired deadline applies only to the notification requirement introduced by RDC 843/2024’s transition rules. It does not create a new deadline for other standing sanitary requirements under RDC 243/2018, such as stability studies and other technical requirements needed to demonstrate product quality and safety. Those obligations remain in force independent of this notification deadline.
The expired deadline was about legacy products, not new entries
If you’re a US or international brand evaluating Brazil for the first time, this specific expired deadline doesn’t apply to you directly, it covered products already on the market before RDC 843/2024 took effect. What it signals instead: ANVISA is actively enforcing its modernized notification system, and treating deadline compliance seriously. A new product entering Brazil today follows the current RDC 843/2024 notification or registration pathway from day one, without this transition grace period.
Legal deadlines that still apply going forward
| Process type | Legal maximum deadline |
|---|---|
| Class I risk product notification | 30 days (RDC 336/2020) |
| Priority-category drug registration | 120 days (Law 13.411/2016) |
| Standard-category drug registration | 365 days (Law 13.411/2016) |
| Response to a technical requirement (exigência) | Minimum 120 days for the company to respond |
Beyond the legal deadline (prazo legal), Brazilian regulatory professionals track the practical processing time (prazo comum), which depends on ANVISA’s caseload, staffing, and submission quality, an incomplete notification can add months to the real timeline, well beyond the legal maximum.
Not sure where your product stands with ANVISA?
Whether you’re navigating this expired deadline for an existing product, or planning a new entry into Brazil, get a direct, current read from a licensed pharmacist who tracks these changes in real time.
Read the Full Market Entry Guide →Related Reading
Brazil’s $4.6 Billion Supplement Market Opportunity FDA vs ANVISA: 5 Critical Differences Which Supplement Ingredients Are Approved in Brazil?Frequently Asked Questions
References: ANVISA, official notice, “Anvisa alerta e orienta sobre o prazo de adequação às regras de regularização de alimentos,” published September 1, 2026. RDC 843/2024. RDC 990/2025, amending Art. 32 of RDC 843/2024. RDC 983/2025. RDC 336/2020. Law 13.411/2016.
Descubra mais sobre FarmaCerto
Assine para receber nossas notícias mais recentes por e-mail.